Redesigning Psychiatry - The new era of biotechnology, the microbiome, and translational neuroscience

This article examines the transformation of psychiatry through the integration of biotechnology, microbiome science, and translational neuroscience. It critiques the traditional neurotransmitter-based model and highlights the limitations of the serotonin hypothesis, emphasizing the need for biologically valid, personalized approaches. The paper reviews evidence linking gut microbiota and the gut-brain axis to mood disorders, discussing psychobiotic therapies that modulate inflammation and neurotransmitter production. It also explores the role of biomarkers, neuroimaging, and frameworks like the Research Domain Criteria (RDoC) in developing precision psychiatry. Finally, the article argues for systemic, multi-level strategies that incorporate genomic, microbial, and behavioral data to redefine diagnosis, treatment, and prevention in mental health.